The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B
 cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of
 stent patency, the incidence of rebleeding and survival in the left and right branches of the
 portal vein were compared.
The most common cause of cirrhosis in China is hepatitis B virus infection; post-hepatitis B
 cirrhosis with gastroesophageal variceal hemorrhage is common in clinical practice; recent
 studies [14] found that implantation of 8 mm diameter is compared with the use of 10 mm
 diameter stents. The membrane stent significantly reduced the incidence of HE after TIPS
 without affecting the shunt effect. To further evaluate the effect of "left/right branch of
 shunt portal" on hepatic encephalopathy after TIPS, we intend to conduct the following
 studies: for individual etiology (post-hepatitis B cirrhosis), the only indication (to
 prevent recurrent rupture of gastroesophageal varices) ), implanted 8mm diameter Viatorr
 stent, unified HE evaluation criteria, and stratified multi-center randomized clinical trial
 study with Child classification, hope to guide TIPS in line with China's national conditions
 through the high-level evidence-based medical evidence obtained.
Inclusion Criteria:

 1. The patient's gender is not limited, ≥ 18 years old and ≤ 75 years old;

 2. Clinically diagnosed post-hepatitis B cirrhosis;

 3. History of esophageal varices venous rupture confirmed by endoscopy, re-bleeding after
 standard treatment;

 4. Liver function Child A or B;

 5. Imaging (CT or MRI) suggests that the left/right first branch of the intrahepatic
 portal can construct a shunt;

 6. Platelet count ≥ 50 × 109 / L;

 7. Prothrombin time (PT) does not exceed the upper limit of the normal control for 3
 seconds;

 8. Serum creatinine concentration ≤115umol/L;

 9. Patients and their families agree to join the clinical trial and sign an informed
 consent form.

 Exclusion Criteria:

 1. Imaging confirms portal vein thrombosis;

 2. Patients who have undergone previous surgical treatment of portal hypertension
 (including splenectomy, surgical disconnection or shunt);

 3. Combine any malignant tumor;

 4. History of previous hepatic encephalopathy;

 5. Consolidation of intractable ascites;

 6. Pulmonary artery pressure > 40 mmHg, left ventricular ejection fraction < 50%,
 congestive heart failure or severe valvular insufficiency;

 7. Others: persistent active bleeding, vital signs can not be maintained, blood ammonia ≥
 100, total bilirubin > 51umol / L failed to improve after symptomatic treatment;
 combined active infection, especially biliary system inflammation; female patients are
 pregnant Or lactation; severe contrast allergy.